BGT-226

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBGT-226
Drug Alias NameBGT-226NVP-BGT226NVP-BGT-226
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMammalian target of Rapamycin (mTORC1) inhibitorsmTOR Complex 2 inhibitorsPI3-kinase class I inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2PI3-kinase class I
Therapy Area/IndicationsSolid tumoursBreast NeoplasmsHamartoma Syndrome, Multiple +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSpain +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsSolid tumoursBreast NeoplasmsHamartoma Syndrome, Multiple +[4] 

Other Information

ATC CodeN/A
Related LinksN/A